TRAP1及其治疗潜力
Andrew Gutierrez1, Jason Archdeacon1, Brian S J Blagg1
1Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, United States.
Bioorganic & medicinal chemistry letters
|September 7, 2025
概括
瘤坏死因子受体相关蛋白1 (TRAP1) 驱动诸如癌症等疾病. 通过调节线粒体功能,TRAP1抑制剂提供了向治疗,可能减少来自更广泛的Hsp90抑制的副作用.
科学领域:
- 线粒体生物学 线粒体生物学
- 分子医学是分子医学.
- 在瘤学瘤学.
背景情况:
- 线粒体Hsp90异型,TRAP1,与癌症,缺血性视网膜病变和糖尿病病等疾病有关.
- TRAP1通过调节线粒体新陈代谢,亡,氧化应激,细胞信号和血管生成通过客户端蛋白相互作用来影响疾病的发病.
研究的目的:
- 审查开发用于减轻Hsp90泛抑制毒性的TRAP1选择性抑制剂.
- 探索TRAP1向疗法的潜在临床应用.
主要方法:
- 对TRAP1抑制剂及其机制的文献综述.
- 分析TRAP1在疾病发病过程中的作用.
- 检查TRAP1导向疗法的临床前和临床数据.
主要成果:
- 通过调节关键细胞过程,TRAP1在各种疾病状态中起着至关重要的作用.
- 选择性TRAP1抑制剂的设计旨在提供有针对性的治疗益处.
- 这些抑制剂旨在减少与非选择性Hsp90抑制剂相关的不良影响.
结论:
- 对于癌症等疾病来说,TRAP1是一个有希望的治疗点.
- 选择性TRAP1抑制剂是治疗疾病的可行策略.
- 需要对TRAP1导向疗法的进一步临床研究.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Transducer Mechanism: Enzyme-Linked Receptors
3.9K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.9K
Enzyme-linked Receptors
86.1K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
86.1K
Therapeutic Drug Monitoring: Overview and Classification
315
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
315
Therapeutic Index
6.7K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
6.7K


